Dossier assessment
Emtricitabine/rilpivirine/tenofovir disoproxil - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Report documents
-
Extract of dossier assessment
Emtricitabine/rilpivirine/tenofovir disoproxil - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
-
Dossier assessment
Emtricitabine/rilpivirine/tenofovir disoproxil - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Press releases
Rilpivirine for HIV: added benefit for single agent proven
Contents of the dossier for the fixed combination product incomplete: existing study data not adequately analysed
Additional information
Federal Joint Committee (G-BA)
2012-07-05 A G-BA decision was published.
Project details
- Project no.
- A12-02
- Commission
- Commission awarded on 13.01.2012 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Drug combination of emtricitabine, rilpivirine and tenofovir disoproxil (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Emtricitabine/rilpivirine/tenofovir disoproxil - Addendum to the benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed